Immunocore Holdings plc (IMCR) stock
IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3017% below fair value
$26.41−0.22 (-0.83%)
Close on Nov 20, 2026Market cap $1.36BP/E –Yield 0.00%
Immunocore shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Immunocore's shares outstanding was 51M at Jun 30, 2026. For fiscal 2025 it was 50M, up 0.7% from the year before. The highest annual figure on record is 50M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 50M | +0.7% |
| FY2024 | Dec 31, 2024 | 50M | +2.3% |
| FY2023 | Dec 31, 2023 | 49M | +6.9% |
| FY2022 | Dec 31, 2022 | 46M | +7.6% |
| FY2021 | Dec 31, 2021 | 42M | +60.2% |
| FY2020 | Dec 31, 2020 | 27M | +19.0% |
| FY2019 | Dec 31, 2019 | 22M | +3.4% |
| FY2018 | Dec 31, 2018 | 22M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 51M | +1.4% |
| Q1 FY2026 | Mar 31, 2026 | 53M | +1.9% |
| Q4 FY2025 | Dec 31, 2025 | 51M | +1.1% |
| Q3 FY2025 | Sep 30, 2025 | 50M | -4.6% |
| Q2 FY2025 | Jun 30, 2025 | 50M | +0.6% |
| Q1 FY2025 | Mar 31, 2025 | 52M | +4.2% |
| Q4 FY2024 | Dec 31, 2024 | 50M | +1.0% |
| Q3 FY2024 | Sep 30, 2024 | 53M | -2.5% |
| Q2 FY2024 | Jun 30, 2024 | 50M | +2.7% |
| Q1 FY2024 | Mar 31, 2024 | 50M | +3.5% |
| Q4 FY2023 | Dec 31, 2023 | 50M | +3.2% |
| Q3 FY2023 | Sep 30, 2023 | 54M | +5.3% |
| Q2 FY2023 | Jun 30, 2023 | 49M | +10.8% |
| Q1 FY2023 | Mar 31, 2023 | 48M | +9.9% |
| Q4 FY2022 | Dec 31, 2022 | 48M | +9.7% |
| Q3 FY2022 | Sep 30, 2022 | 51M | – |
| Q2 FY2022 | Jun 30, 2022 | 44M | – |
| Q4 FY2021 | Dec 31, 2021 | 44M | – |
| Q3 FY2021 | Sep 30, 2021 | 44M | – |
See a number that looks wrong?